 Multiple myeloma VMCP/VBAP combination chemotherapy superior high-risk patients efficacy vincristine melphalan prednisone/vincristine carmustine doxorubicin prednisone VMCP/VBAP polychemotherapy prednisone MP regimen induction treatment multiple myeloma MM MM patients study March July analysis December treatment groups significant differences respect major prognostic factors Median overall survival months VMCP/VBAP MP arms induction chemotherapy cycles patients component reduction significant difference treatment arms terms remission duration months survival months Patients years advantage polychemotherapy diagnosis plasma cell index LI serum microglobulin patients survival patients LI equal months equal mg/L months poor-risk subgroups VMCP/VBAP superior MP